Terms: = Prostate cancer AND ELN, ENSG00000049540, 2006, WS, WBS, SVAS, FLJ43523, FLJ38671 AND Staging
66 results:
1. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
2. The Rate of Prostatic Involvement in Men Treated With Radical Cystectomy for Muscle Invasive Bladder cancer.
Royal-Preyra B; Cury FL; Katib Y; Monsoor M; Brimo F; Kassouf W; Souhami L
Pract Radiat Oncol; 2023; 13(1):e68-e72. PubMed ID: 35901948
[TBL] [Abstract] [Full Text] [Related]
3. Local Extent of prostate cancer at MRI versus prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
Wibmer AG; Nikolovski I; Chaim J; Lakhman Y; Lefkowitz RA; Sala E; Carlsson SV; Fine SW; Kattan MW; Hricak H; Vargas HA
Radiology; 2022 Mar; 302(3):595-602. PubMed ID: 34931855
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
Fukunaga A; Maejima A; Shinoda Y; Matsui Y; Komiyama M; Fujimoto H; Miyagi Maeshima A
Int J Urol; 2021 Oct; 28(10):1039-1045. PubMed ID: 34291506
[TBL] [Abstract] [Full Text] [Related]
5. Prediction of Pathologic Findings with MRI-Based Clinical staging Using the Bayesian Network Modeling in prostate cancer: A Radiation Oncologist Perspective.
Wee CW; Jang BS; Kim JH; Jeong CW; Kwak C; Kim HH; Ku JH; Kim SH; Cho JY; Kim SY
Cancer Res Treat; 2022 Jan; 54(1):234-244. PubMed ID: 34015891
[TBL] [Abstract] [Full Text] [Related]
6. Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis.
Wettstein MS; David LA; Pazhepurackel C; Qureshi AA; Zisman A; Nesbitt M; Saba K; Herrera-Caceres JO; Fankhauser CD; Ahmad A; Hamilton RJ; Eberli D; Zlotta AR; Sulser T; Fleshner NE; Poyet C; Finelli A; Hermanns T; Kulkarni GS
Prostate; 2021 Apr; 81(5):286-294. PubMed ID: 33599318
[TBL] [Abstract] [Full Text] [Related]
7. Examined and Positive Lymph Node Counts Are Associated with Mortality in prostate cancer: A Population-Based Analysis.
Kamel MG; Istanbuly S; Abd-Elhay FA; Mohamed MYF; Huu-Hoai L; Sadik M; Dibas M; Huy NT
Urol Int; 2020; 104(9-10):699-709. PubMed ID: 32268338
[TBL] [Abstract] [Full Text] [Related]
8. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract] [Full Text] [Related]
9. Significance of examined lymph-node count in accurate staging and long-term survival in patients undergoing radical prostatectomy: a population-based study.
Chen C; Shen J; Xing Z; Jiang C; Hu L; Cui L; Xue D; He X; Xu R
Int Urol Nephrol; 2020 Feb; 52(2):271-278. PubMed ID: 31571158
[TBL] [Abstract] [Full Text] [Related]
10. Assessing a modified-AJCC TNM staging system in the New South Wales cancer Registry, Australia.
Lawrance S; Bui C; Mahindra V; Arcorace M; Cooke-Yarborough C
BMC Cancer; 2019 Aug; 19(1):850. PubMed ID: 31462255
[TBL] [Abstract] [Full Text] [Related]
11. Prediction of Organ-confined Disease in High- and Very-high-risk prostate cancer Patients Staged with Magnetic Resonance Imaging: Implications for Clinical Trial Design.
Reichard CA; Kukreja J; Gregg JR; Bathala TK; Achim MF; Wang X; Davis JW; Nguyen QN; Chapin BF
Eur Urol Focus; 2021 Jan; 7(1):71-77. PubMed ID: 31076357
[TBL] [Abstract] [Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract] [Full Text] [Related]
13. Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
Huang MH; Blackwood J; Godoshian M; Pfalzer L
PLoS One; 2018; 13(12):e0208573. PubMed ID: 30566443
[TBL] [Abstract] [Full Text] [Related]
14. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series.
Mohler JL; Halabi S; Ryan ST; Al-Daghmin A; Sokoloff MH; Steinberg GD; Sanford BL; Eastham JA; Walther PJ; Morris MJ; Small EJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):309-316. PubMed ID: 30385835
[TBL] [Abstract] [Full Text] [Related]
15. Targeted prostate Biopsy and MR-Guided Therapy for prostate cancer.
Woodrum DA; Kawashima A; Gorny KR; Mynderse LA
Adv Exp Med Biol; 2018; 1096():159-184. PubMed ID: 30324353
[TBL] [Abstract] [Full Text] [Related]
16. Surgeon-led prostate cancer lymph node staging: pathological outcomes stratified by robot-assisted dissection templates and patient selection.
Altok M; Babaian K; Achim MF; Achim GC; Troncoso P; Matin SF; Chapin BF; Davis JW
BJU Int; 2018 Jul; 122(1):66-75. PubMed ID: 29446205
[TBL] [Abstract] [Full Text] [Related]
17. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.
Gandaglia G; Zaffuto E; Fossati N; Bandini M; Suardi N; Mazzone E; Dell'Oglio P; Stabile A; Freschi M; Montorsi F; Briganti A
BJU Int; 2018 Mar; 121(3):421-427. PubMed ID: 29063734
[TBL] [Abstract] [Full Text] [Related]
18. Erectile Function Recovery after Radical prostatectomy in Men with High Risk Features.
Recabal P; Assel M; Musser JE; Caras RJ; Sjoberg DD; Coleman JA; Mulhall JP; Parra RO; Scardino PT; Touijer K; Eastham JA; Laudone VP
J Urol; 2016 Aug; 196(2):507-13. PubMed ID: 26905018
[TBL] [Abstract] [Full Text] [Related]
19. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National cancer Data Base.
Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
[TBL] [Abstract] [Full Text] [Related]
20. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized prostate cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Blanchard P; Faivre L; Lesaunier F; Salem N; Mesgouez-Nebout N; Deniau-Alexandre E; Rolland F; Ferrero JM; Houédé N; Mourey L; Théodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Davin JL; Habibian M; Culine S; Laplanche A; Fizazi K
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):85-92. PubMed ID: 26576711
[TBL] [Abstract] [Full Text] [Related]
[Next]
